376646-62-7Relevant articles and documents
3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF
-
Page/Page column 55-56; 81-82, (2022/04/09)
Disclosed herein is 3- [ (1H-pyrazol-4-yl) oxy] pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g., inhibiting or treating HPK1 related disorders or diseases including cancer by using the compound disclosed herein
COMPOUNDS USEFUL IN INHIBITING DIACYLGLYCEROL O-ACYLTRANSFERASE AND METHODS OF MAKING AND USING THE SAME
-
Page/Page column 25, (2021/08/20)
Described herein are compounds that may act as an inhibitor of diacylglycerol O- acyltransferase 2 (DGAT2) and/or that may be useful in the treatment of diseases and/or disorders associated with DGAT2. Compositions including such compounds are also described herein along with methods of preparation and use of such compounds and/or compositions.
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases
Ma, Bin,Bohnert, Tonika,Otipoby, Kevin L.,Tien, Eric,Arefayene, Million,Bai, Judy,Bajrami, Bekim,Bame, Eris,Chan, Timothy R.,Humora, Michael,Macphee, J. Michael,Marcotte, Douglas,Mehta, Devangi,Metrick, Claire M.,Moniz, George,Polack, Evelyne,Poreci, Urjana,Prefontaine, Annick,Sheikh, Sarah,Schroeder, Patricia,Smirnakis, Karen,Zhang, Lei,Zheng, Fengmei,Hopkins, Brian T.
, p. 12526 - 12541 (2020/12/17)
Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine producti
INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
-
Page/Page column 40; 41, (2020/11/30)
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
-
Page/Page column 48, (2019/12/04)
Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, methods for use as Bruton's tyrosine kinase and methods of production.
PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER
-
Paragraph 00224; 00509; 00510, (2017/05/02)
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of t
ADIPATE FORMS AND COMPOSITIONS OF BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Paragraph 0114, (2016/12/26)
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
-
Paragraph 0617, (2015/06/25)
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
-
Paragraph 0195, (2015/06/25)
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
SUBSTITUTED QUINOLONES
-
Page/Page column 51, (2010/02/15)
The invention relates to substituted quinolones methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular, for use as antiviral agents, in particular, against cytomegaloviruses.